After 4 weeks of failed conventional therapy—

Choose the ONLY bioengineered, bilayered, living cell–based product for venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs)\(^1\)

**Description**
- Apligraf contains 2 cell types derived from neonatal foreskin: living human keratinocytes and fibroblasts embedded in a type 1 collagen matrix\(^1\)

**Indication**
- Apligraf is the ONLY treatment with FDA approval for healing both venous leg ulcers (VLUs) after 4 weeks of failed conventional therapy and diabetic foot ulcers (DFUs) after 3 weeks of failed conventional therapy\(^1\)

**Cell viability**
- Apligraf is delivered ready to use with >90% cell viability throughout its 15-day shelf life\(^2\)

**Faster healing**
- Patients with VLUs treated with Apligraf healed in 99 days (n=130) vs 184 days with conventional therapy alone (n=110) \([P=0.0074]\)\(^2,a\)
- Patients with DFUs treated with Apligraf healed in 65 days (n=112) vs 90 days with conventional therapy alone (n=96) \([P=0.0026]\)\(^3,b\)

**More complete wound closure**
- More patients achieved 100% closure with Apligraf plus conventional therapy vs conventional therapy alone (VLUs = 57% vs 40% \([P=0.0223]\); DFUs = 56% vs 38% \([P=0.0042]\))\(^1,3,c,d\)
- The majority of both VLU and DFU patients received an average of 3 or more applications\(^2,e,f\)
Faster Healing.  
Consistent Reimbursement Coverage.

Access Apligraf® with ease
- Medicare: Apligraf is covered by 100% of local coverage determinations (LCDs)
- Medicaid: Covered by ~90% of state programs
- Commercial insurance: Apligraf is covered by >1500 plans
- No insurance: Apligraf is available through our Patient Assistance Program

When conventional therapy is not leading to wound closure, achieve faster healing and more complete closure with Apligraf

To order Apligraf or for more information, call 1.888.HEAL.2.DAY (1.888.432.5232)


Please see complete prescribing information enclosed, or visit www.Apligraf.com

© 2011 Organogenesis Inc. OI-A1005. All rights reserved. Printed in U.S.A. 6/11
Apligraf is a registered trademark of Novartis.